Our Technology

PLxGuardTM Drug Delivery Platform

Some active pharmaceutical ingredients (APIs) may cause injury to the stomach lining.
Preassociating the API with a unique phospholipid prevents the API from interacting with similar naturally occurring phospholipids in the gastric mucosal barrier, helping to prevent local gastric injury.
This preassociation makes it less likely that APIs will come in direct contact with the stomach.

The unique complex remains stable in low pH, limiting direct contact of the API within the GI tract.

Complex limiting contact with gastric mucosa
Complex helps protect against direct stomach contact

The complex employs a pH-dependent release mechanism that selectively releases the API in higher pH environments within the GI tract. The API is quickly and completely absorbed, delivering predictable drug effects.

Complex in higher-pH environment of the duodenum
Targeted delivery to optimize absorption

Even if reflux occurs and the API and lipidic excipients return to the stomach, they reassemble into the complex, limiting direct stomach contact.

Complex limiting contact with gastric mucosa
Reduces contact with stomach even if reflux occurs

PLxGuardTM may have the potential to:

  • Enhance delivery of active pharmaceutical ingredients
  • Optimize drug absorption and reduce local GI injury
  • Provide new or extended patent protection for an already approved or development-stage drug
  • Utilize the 505(b)(2) NDA regulatory path that often provides a faster and lower-cost FDA approval when used with already approved drugs

GI: gastrointestinal, NDA: new drug application, NSAID: nonsteroidal anti-inflammatory drug